Recent Quotes (30 days)

You have no recent quotes
chg | %

SeaSpine Holdings Corp  

(Public, NASDAQ:SPNE)   Watch this stock  
Find more results for SPNE
10.14
+0.07 (0.70%)
Nov 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.02 - 10.22
52 week 6.31 - 13.46
Open 10.02
Vol / Avg. 16,446.00/29,712.00
Mkt cap 136.17M
P/E     -
Div/yield     -
EPS -2.91
Shares 13.43M
Beta     -
Inst. own 42%
Nov 28, 2017
SeaSpine Holdings Corp at Piper Jaffray Healthcare Conference - 11:30AM EST - Add to calendar
Nov 2, 2017
Q3 2017 SeaSpine Holdings Corp Earnings Call - Webcast
Nov 2, 2017
Q3 2017 SeaSpine Holdings Corp Earnings Release
Oct 26, 2017
SeaSpine Holdings Corp Corporate Analyst Meeting - Webcast
Sep 26, 2017
SeaSpine Holdings Corp at Cantor Fitzgerald Global Healthcare Conference
Sep 12, 2017
SeaSpine Holdings Corp at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -23.51% -33.53%
Operating margin -24.37% -33.76%
EBITD margin - -20.40%
Return on average assets -21.18% -26.71%
Return on average equity -27.66% -33.46%
Employees 310 -
CDP Score - -

Address

5770 Armada Dr
CARLSBAD, CA 92008-4608
United States - Map
+1-760-7278399 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

SeaSpine Holdings Corporation is a medical technology company. The Company is focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Company operates through the development, manufacture and marketing of orthobiologics and spinal fusion hardware segment. It has a portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures in the lumbar, thoracic and cervical spine. It offers a portfolio of orthobiologics and spinal fusion hardware products for the treatment of patients suffering from spinal and other orthopedic disorders. Its orthobiologics products consist of a range of bone graft substitutes that are designed to improve bone fusion rates following a range of orthopedic surgeries, including spine, hip and extremities procedures.

Officers and directors

Keith C. Valentine President, Chief Executive Officer
Bio & Compensation  - Reuters
John J. Bostjancic Chief Financial Officer, Treasurer, Secretary
Bio & Compensation  - Reuters
Paul Benny Vice President, Controller, Assistant Treasurer, Assistant Secretary
Bio & Compensation  - Reuters
Troy Woolley Vice President - Marketing, Spine Hardware
Bio & Compensation  - Reuters
Brian Baker Vice President, Global Operations
Bio & Compensation  - Reuters
Colin Smith Vice President, Product Development and Marketing
Bio & Compensation  - Reuters
John Winge President, Sales
Bio & Compensation  - Reuters
Patrick L. Keran J.D. General Counsel
Age: 43
Bio & Compensation  - Reuters
William Rhoda General Manager - Process Innovation and Development
Bio & Compensation  - Reuters